For adults with moderate to severe Crohn’s disease in whom TNF blockers did not work well

For adults with moderate to severe Crohn’s disease in whom TNF blockers did not work well

Proven results

with RINVOQ

RINVOQ results that won’t back down

Many people(~4 out of 10) taking RINVOQ achieved

Remission

meaning few or no symptoms (at 12 weeks and 1 year)

Click on the tabs below to see proven RINVOQ results

aa
In Study 1, 2.6 times more people, 37% taking RINVOQ 45 mg (N=273) experienced rapid symptom relief vs 14% on placebo (N=146).
In Study 1, 2.6 times more people, 37% taking RINVOQ 45 mg (N=273) experienced rapid symptom relief vs 14% on placebo (N=146). In Study 2, 1.5 times more people, 37% taking RINVOQ 45 mg (N=295) experienced rapid symptom relief vs 24% on placebo (N=143).
In Study 1, 2.7 times more people, 30% taking RINVOQ 45 mg (N=96) achieved steroid-free remission vs 11% on placebo (N=53).
In Study 1, 2.7 times more people, 30% taking RINVOQ 45 mg (N=96) achieved steroid-free remission vs 11% on placebo (N=53). In Study 2, 3 times more people, 40% taking RINVOQ 45 mg (N=108) achieved steroid-free remission vs 13% on placebo (N=54).
In Study 1, 11 times more people, 34% taking RINVOQ 45 mg (N=273) experienced visibly reduced damage of the intestinal lining vs 3% on placebo (N=146).

*Based on areas that were assessed with endoscopy.

In Study 1, 11 times more people, 34% taking RINVOQ 45 mg (N=273) experienced visibly reduced damage of the intestinal lining 3% on placebo (N=146). In Study 2, 3.5 times more people, 46% taking RINVOQ 45 mg (N=295) experienced visibly reduced damage of the intestinal lining vs 13% on placebo (N=143).

*Based on areas that were assessed with endoscopy.

In Study 3, 3 times more people, 42% taking RINVOQ 15 mg (N=113) & 53% taking RINVOQ 30 mg (N=119) achieved steroid-free remission vs 14% on placebo (N=111).
In Study 3, 4 times more people, 28% taking RINVOQ 15 mg (n=113) & 41% taking RINVOQ 30 mg (n=119) experienced visibly reduced damage of the intestinal lining vs 7% on placebo (n=111).

*Based on areas that were assessed with endoscopy.

SAFETY CONSIDERATIONS

RINVOQ may cause serious side effects, including:

  • Serious infections. RINVOQ can lower ability to fight infections. Serious infections, some fatal, occurred, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Blood clots, some fatal, in veins of the legs or lungs and arteries. This occurred more often in people 50+ with at least 1 heart disease risk factor.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.
  • Tears in the stomach or intestines; changes in certain laboratory test results.

Learn more about these and the full Important Safety Information below. 

Keep scrolling to see trial data and real patient endoscopy images at 12 weeks and 1 year

aa

PATIENT 1

Real clinical trial patient endoscopy images. Adult patient with moderate to severe Crohn's disease received RINVOQ 45 mg (induction) and 15 mg (maintenance), once daily. Patient had previously used a medicine called a tumor necrosis factor (TNF) blocker that either did not work well or could not be tolerated.

Patient 1’s rectum before taking RINVOQ showing visible intestinal lining damage

Before RINVOQ

Patient 1’s rectum at week 12 on RINVOQ showing little to no visible evidence of active Crohn's (endoscopic remission)

Week 12

Patient 1’s rectum after 1 year on RINVOQ showing little to no visible evidence of active Crohn's (endoscopic remission)

1 Year

Patient achieved endoscopic remission at Week 12 and also at 1 year. At 12 weeks, 19% of people taking RINVOQ 45 mg (N=273) achieved endoscopic remission (little to no visible evidence of active Crohn’s) vs 3% of patients taking placebo (N=146) in Study 1. At 1 year, 19% of people taking RINVOQ 15 mg (N=113) achieved endoscopic remission (little to no visible evidence of active Crohn’s) vs 5% of patients taking placebo (N=111) in Study 3.

Individual results may vary.

PATIENT 2

Real clinical trial patient endoscopy images. Adult patient with moderate to severe Crohn's disease received RINVOQ 45 mg (induction) and 30 mg (maintenance), once daily. Patient had previously used a medicine called a tumor necrosis factor (TNF) blocker that either did not work well or could not be tolerated.

Patient 2’s rectum before taking RINVOQ showing visible intestinal lining damage

Before RINVOQ

Patient 2’s rectum at week 12 on RINVOQ showing visibly reduced intestinal lining damage (endoscopic response)

Week 12

Patient 2’s rectum after 1 year on RINVOQ showing visibly reduced intestinal lining damage (endoscopic response)

1 Year

Patient achieved endoscopic response at Week 12 and also at 1 year. 

Individual results may vary.

Your doctor will decide which maintenance dose (15 mg or 30 mg) is right for you.

In clinical studies,

RINVOQ helped people achieve visibly reduced damage of the intestinal lining (endoscopic response).*

At 12 weeks, 34% of people taking RINVOQ 45 mg (N=273) achieved visibly reduced damage of the intestinal lining* vs 3% of patients taking placebo (N=146) in Study 1, and 46% of people taking RINVOQ 45 mg (N=295) vs 13% of patients taking placebo (N=143) in Study 2.

At 1 year, 28% of people taking RINVOQ 15 mg (N=113) and 41% of people taking RINVOQ 30 mg (N=119) achieved visibly reduced damage of the intestinal lining* vs 7% of patients taking placebo (N=111) in Study 3.

*Based on endoscopy at 12 weeks and 1 year.

 

Understanding the possible side effects of RINVOQ

Consider the benefits and risks of taking RINVOQ to make an informed treatment choice with your gastroenterologist.

Quick poll

Still experiencing Crohn’s disease symptoms after a TNF blocker like HUMIRA® or REMICADE®?

RINVOQ is a once-daily pill that treats patients with moderate to severe Crohn’s disease in whom TNF blockers did not work well. It’s important to continue to partner with your gastroenterologist.

What is RINVOQ? >

RINVOQ is a once-daily pill that treats patients with moderate to severe Crohn’s disease in whom TNF blockers did not work well. It’s important to continue to partner with your gastroenterologist.

What is RINVOQ? >

REMICADE® (infliximab) is a registered trademark of Janssen Biotech, Inc.

Make a

Discover how RINVOQ works

with a gastroenterologist

Find a doctor who understands your treatment goals.

Is your current treatment meeting your goals?

Use our discussion tool to help start a conversation with your doctor.

Looking for a specialist to help treat your Crohn’s disease?

Find a gastroenterologist near you.